Grand Finale · All Three Skills Combined

Integrated C-Suite Decision Package

Grand Finale — evidence integrated across clinical development, commercial strategy and enterprise operations into one Go/No-Go for a novel therapy launch (Project NOVATRA).

Executive Leadership Team decision package · Clinical × Market × Strategy · Integrated Go/No-Go · Generated with Claude Code

CEO Executive Summary

Unified C-suite decision package for Project NOVATRA — clinical, commercial and enterprise evidence on one page

Integrated Decision

58/100

CONDITIONAL GO

Clinical / Regulatory

55/100

efficacy-gated

Market Opportunity

51/100

Oncology lead

Strategic Fit

49/100

portfolio-aligned

Financial Return

75/100

116% blended ROI

Addressable Market

$227B

13.0% CAGR

Enterprise Revenue

$75.6B

25% EBITDA

Key Risk

d=0.04

efficacy magnitude

To the Executive Leadership Team — integrating evidence across clinical development, commercial strategy and enterprise operations, Project NOVATRA earns a CONDITIONAL GO (58/100). The commercial and strategic case is strong: a $227B addressable market growing 13.0%, a well-fitting 25%-Star portfolio, and 116% blended enterprise ROI. The binding constraint is clinical: the lead asset is statistically significant but the effect size is negligible (Cohen's d=0.04), so the decision hinges on whether the efficacy magnitude can be strengthened before filing.

What is compelling

Market & money. Oncology is the most attractive TA (opp 6855), safety is clean (SAE balanced across arms, p=0.68), and the portfolio economics support launch investment.

What is gating

Efficacy magnitude. High-dose vs placebo is significant (p=0.002) but clinically negligible (d=0.04, ~1.3 pts / 100). A launch cannot rest on a p-value alone.

The decision

Conditional. Proceed with launch readiness in parallel, but gate the filing on a pre-specified efficacy re-analysis and a benefit-risk that clears a minimum clinically important difference.

Integrated Decision Scorecard

Four evidence dimensions, weighted into one Go/No-Go

Dimension scores (weighted)

Dimension	Score	Weight	Contribution	Read
Clinical / Regulatory	55/100	30%	16.5	Adequate
Market Opportunity	51/100	25%	12.8	Adequate
Strategic Fit	49/100	20%	9.8	Weak
Financial Return	75/100	25%	18.8	Strong
INTEGRATED	58/100	100%	58	CONDITIONAL GO

Dimension radar

Clinical Efficacy, Safety & Regulatory Readiness

Lead-asset evidence from the 30,000-subject integrated trial database

Efficacy Δ (High vs PBO)

+1.28

p=0.002

Effect size

d=0.04

negligible (<0.2)

SAE balance

p=0.68

no arm signal

Data completeness

99.1%

readiness 82/100

Efficacy by arm

Means differ by ~1 point on a 0–100 scale — statistically significant, clinically negligible

Regulatory readiness

Control	Status
HIPAA de-identified	100%
GCP site pass	50%
Data completeness	99%
Protocol adherence	50%
Safety signal	None (balanced)

Regulatory-ready on integrity & safety; the gate is efficacy magnitude (d=0.04). See Dashboard 1 for the full estimand strategy.

Market Attractiveness & Launch Opportunity

Where Oncology launches into, and how big the prize is

TAM

$227B

total addressable

SAM

$152B

reachable

SOM

$15.1B

obtainable

Lead TA

Oncology

13.1% CAGR

Therapy-area opportunity

Composite opportunity score

TAM → SAM → SOM

Competitor Benchmarking & Payer Landscape

Who we compete with, and who pays

Captured revenue by competitor

Novartis leads the tracked universe

Payer mix

Private 34%

Government 33%

Mixed 33%

Access read: government payers are material in this market, so a differentiated value/HEOR story is required. With efficacy marginal (§03), access risk is elevated — payers reward magnitude of benefit, and a ~1-point endpoint gain is a weak negotiating position.

Portfolio Fit — BCG & GE-McKinsey

Does Project NOVATRA fit the enterprise portfolio?

Enterprise BCG revenue mix

Star 25%

Cash Cow 25%

Question Mark 25%

Dog 25%

GE-McKinsey — client business units

Fit verdict: strong. Project NOVATRA targets Oncology — a high-attractiveness space — and the enterprise already carries a 25% Star-weighted book with 50/100 competitive strength. The asset would enter as a Question Mark with Star potential, contingent on the §03 efficacy gate.

Financial Projections, ROI & Investment Scenarios

Five-year launch economics for Project NOVATRA

Revenue vs. investment ($B)

S-curve uptake against launch investment

Cumulative cash flow ($B)

Breakeven where the line crosses zero

Peak revenue (Yr5)

$0.82B

36% peak share of SOM

Enterprise ROI

116%

blended portfolio benchmark

Break-even

beyond Yr5

cumulative cash-flow positive

Illustrative launch model: net revenue = peak × S-curve uptake; investment front-loaded. A committee model would add gross-to-net, COGS and probability-of-success weighting.

Enterprise Risk Register & Mitigation

Cross-domain risks with probability, impact, mitigation and owner

Integrated risk register

Risk	Prob.	Impact	Mitigation	Owner
Efficacy magnitude below MCID	High	Critical	Pre-specified re-analysis + biomarker-enriched subpopulation; gate filing	CMO
Payer rejection on weak benefit	High	High	Early HEOR + value-based contracting; managed-entry agreement	Market Access
Patent cliff exposure (2028)	Medium	High	Lifecycle-management filings ahead of 2028; formulation strategy	CSO
GCP site quality (Review-flagged)	Medium	Medium	CAPA + targeted SDV on high-risk sites (RBM)	Head of Clin Ops
Data-quality (SAE anomaly)	Medium	Medium	Source-data verification & reconciliation before lock	Data Management
Digital/AI capability gap	Medium	Medium	Fund enterprise AI program; close maturity gap	CDO
Competitive entry / share erosion	Medium	High	Differentiate on access & real-world evidence	CCO

AI & Digital Transformation Opportunities

Cross-functional AI value map

Digital maturity today

AI value map by function

R&D: AI trial design, synthetic control arms, biomarker discovery to rescue the efficacy signal.
Medical: automated safety signal detection & literature surveillance.
Commercial: payer analytics, next-best-action, launch-uptake forecasting.
Supply chain: demand sensing & network optimization for launch readiness.
Governance: ISO 42001 / NIST AI RMF, human-in-the-loop for regulated outputs.

Strategic tie-in: AI-enabled biomarker enrichment is the most direct lever on the §03 efficacy gate — identifying a responder subpopulation could convert a negligible all-comers effect into a meaningful targeted one.

Cross-Functional Implementation Roadmap

R&D · Medical · Commercial · Supply Chain — synchronized to the launch decision

R&D

Pre-specified efficacy re-analysis & estimand robustness.
Biomarker-enriched subpopulation study.
Design label-expansion protocol.

Medical Affairs

KOL engagement in Oncology.
Publication & evidence-generation plan.
Safety monitoring board stand-up.

Commercial & Market Access

Early payer advisory + HEOR dossier.
Value-based / managed-entry contracting.
Launch-readiness & uptake model.

Supply Chain

Launch supply plan + 4-month safety stock.
Demand-sensing analytics.
Serialization & multi-market readiness.

30-60-90 Day Execution Plan

Immediate moves to de-risk the decision

First 30 days

Charter the integrated launch steering committee.
Commission the pre-specified efficacy re-analysis.
Baseline the 12-KPI monitoring framework (§13).

Days 31–60

Payer advisory boards + HEOR model kickoff.
Biomarker-enrichment feasibility read-out.
Supply & MSL launch-readiness plans.

Days 61–90

Go/No-Go gate: confirm efficacy path before filing commit.
Lock launch investment envelope.
Report integrated score movement to the board.

Three-Year Strategic Roadmap

From conditional go to differentiated launch

Year 1 — De-risk & decide

Resolve the efficacy gate (re-analysis / enrichment).
Regulatory filing if gate clears.
Secure Day-1 payer access.

Year 2 — Launch & scale

Launch in Oncology; drive uptake curve.
Real-world evidence generation.
AI-enabled commercial & supply ops.

Year 3 — Expand & defend

Label / geographic expansion.
LOE defense ahead of 2028.
Portfolio reallocation to Star-track.

Executive Dashboard Specification

KPIs, visualizations and monitoring cadence for the launch

Board monitoring framework

KPI	Domain	Baseline / Target	Visualization	Cadence
Integrated Go/No-Go score	Cross	58/100 → ≥70	Gauge	Monthly
Efficacy effect size (d)	Clinical	0.04 → ≥0.20	Forest plot	Per readout
Regulatory readiness	Clinical	82 → ≥90	Scorecard	Monthly
Formulary access (% lives)	Commercial	0 → 60% by M6	Trend line	Monthly
Launch uptake vs curve	Commercial	— → on-plan	S-curve	Weekly
Peak revenue trajectory	Financial	0.8B target	Waterfall	Quarterly
Enterprise risk score	Strategy	51 → <45	Heatmap	Quarterly
Digital maturity	Strategy	3.0/5 → ≥3.5	Bar	Half-yearly

Board Recommendation & Go/No-Go

Final integrated recommendation for Project NOVATRA

Recommendation: CONDITIONAL GO

Approve CONDITIONAL GO for Project NOVATRA: proceed with launch preparation in parallel, but gate the regulatory filing on resolving the efficacy magnitude.

Commercial & strategic case is strong — $227B market, 13.0% growth, strong portfolio fit, 116% enterprise ROI.
Safety is clean — no differential SAE signal (p=0.68); data is regulatory-grade.
The one gate: efficacy is statistically significant but clinically negligible (d=0.04). Resolve via pre-specified re-analysis and biomarker enrichment before filing.
The ask: fund the 90-day de-risking sprint (§11) and a ring-fenced launch envelope, with a hard Go/No-Go gate at day 90.

One-line verdict: the market wants this launch and the enterprise can afford it — the science has to earn it. Conditional go, science-gated.

Synthesized from all three source datasets (clinical 30,000 subjects · market 30,000 asset-records · strategy 30,000 projects). Dimension scores and the integrated Go/No-Go are transparent weighted composites; the efficacy finding is reported honestly (statistically significant, clinically negligible). Demonstration decision analytic, not investment or regulatory advice.